BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Names Charlie Harte Director of Field Sales & Recruiting - Canada12.10.2026 16:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Charlie Harte joins Chervon as Director of Field Sales and Recruiting - Canada, effective Monday, October 12, 2026, reporting to Neil Harrison, VP/MD Sales and Marketing - Canada. Harte brings 15+ years of experience in the Canadian power tools, outdoor power equipment, and hand tool market. Additionally, he has 6+ years of experience selling into the commercial plumbing arena. Early in his career, Harte spent six years at Black and Decker growing into the National Sales and Marketing Manager position for B&D Canada. He subsequently became Director of Sales for Irwin Industrial Tools and then became a Director of Sales for Milwaukee Canada. Harte moved into the VP Sales position for Uponor Advanced Plumbing Solutions. Harte has an impressive track record in field sales leadership and strategic account development. He is known for his ability to build and manage high-performance sales teams throughout Canada. "Charlie brings an outst
Chervon Names Thomas G. Kentouris Vice President of Field Sales12.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Thomas G. Kentouris joins Chervon as Vice President of Field Sales, effective Monday, October 12, 2026, reporting to Matt DeFeo, SVP of Sales Training and Recruiting. Kentouris brings 14+ years of Power Tool and Outdoor Power Equipment experience at TTI. His career began as a sales rep and advanced through a series of increasingly responsible positions, culminating in SVP of Field Sales for Eastern U.S.A. Kentouris delivered exceptional sales growth results year after year in his areas of responsibility. His ability to develop store-level partnerships and store-level sell-through programs all resulted in exceptional levels of success. Kentouris distinguished himself as an outstanding recruiting talent as he and his teams were responsible for recruiting over 2,000 high potential recent college graduates into the TTI system. Kentouris did an amazing job mentoring, developing, and promoting hundreds of his people into higher level posi
Chervon Names Randall Durkan Vice President of Supply Chain - North America12.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Randy Durkan joins Chervon as Vice President of Supply Chain - North America, effective Monday, October 12, 2026, reporting to CEO Joe Galli. Randy Durkan brings over 25 years of supply chain management experience, including extensive leadership in power tools, hand tools, and outdoor power equipment. He has proven experience building high-performance supply chain teams and has consistently delivered outstanding service levels, inventory optimization, and cost-reduction results. Durkan is known for developing strong supply chain partnerships with key customers, driving cross-functional collaboration, and deploying technology to achieve world-class supply chain performance. He began his early supply chain career in Bentonville, Arkansas, supporting Walmart-focused collaboration across several consumer goods companies. His work at Vi-Jon contributed to Walmart's 2008 Supplier of the Year Award. Durkan then spent six years in supply ch
Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 20269.10.2026 17:00:00 CEST | Press release
MIAMI, FL / ACCESS Newswire / October 9, 2026 / Miami Fashion Week® (MIAFW) celebrates its 10th anniversary this year, returning October 13-18, 2026 featuring industry programming, runway shows, and special events bringing together international designers, Latin American talent and Miami's creative community. For a decade, MIAFW has served as a bridge between Miami and the international fashion industry, creating a platform for designers while expanding beyond the runway through sustainability, technology, education and cultural exchange. The milestone edition brings together international designers, Latin American talent, fashion innovation and a new Stitch Lab retail experience Throughout these ten years, MIAFW has pioneered initiatives at the intersection of fashion, sustainability and technology. Founded in 2017, the MIAFW Summit created a space for dialogue and education around the industry's evolving challenges and opportunities. Building on that vision, the Virtual Fashion Award
IROS 2026|PaXini Showcases Full-Stack Tactile Strategy for Physical AI8.10.2026 18:15:00 CEST | Press release
PITTSBURGH, PA / ACCESS Newswire / October 8, 2026 / As global researchers and industry leaders gathered in Pittsburgh for IROS 2026 (Sep. 27-Oct. 1) to tackle the scaling of Physical AI, PaXini AI took center stage, showcasing its full-stack products from chips to humanoid robots and hosting GEEN 2026 · IROS, the Global Embodied Ecosystem Night. The event was not merely an exchange, but an industry gathering focused on the deployment of embodied intelligence. As a leader in tactile sensing, PaXini has built a full-stack closed loop centered on touch: PIE - Perception, Intelligence, Execution. Perception enables robots to understand the real environment more comprehensively and accurately. Intelligence uses data and experience to move robots from being programmed to adapting and generalizing. Execution, through powerful actuators and dexterous end-effectors, allows robots to complete complex tasks. These three layers drive one another and form PaXini's infrastructure capability for the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom